文献速递儿童神经与发育行为

自闭症谱系障碍幼儿的治疗与精神药物使用情况

Therapy and Psychotropic Medication Use in Young Children With Autism Spectrum Disorder.
PubMed 文献 · Pediatrics · 2020-01-01

本研究基于Autism Speaks自闭症治疗网络(AS-ATN)注册数据,分析了3-6岁自闭症谱系障碍(ASD)患儿接受干预的情况。结果显示,每周治疗总时间中位数为5.5小时,仅33.4%的患儿接受行为治疗,16.3%的患儿使用至少一种精神药物;入组前ASD诊断是治疗总时间的显著预测因素,而地点区域是精神药物使用的显著预测因素。

要点

  • 每周治疗总时间中位数为5.5小时,仅33.4%的幼儿接受行为治疗。
  • 16.3%的患儿使用至少一种精神药物,且存在地区差异。
  • 入组前ASD诊断可预测治疗总时间,地点区域可预测精神药物使用。

核心结论

  • 相对较少的ASD幼儿正在接受行为治疗或达到推荐强度的总治疗时间。
  • 精神药物使用存在地区变异性。
  • 需要进一步研究以改善ASD幼儿获得循证治疗的机会。

研究设计与样本

  • 研究分析了AS-ATN注册数据,该注册库包含美国和加拿大17个中心的ASD儿童。
  • 参与者接受诊断评估和治疗建议,父母在随访时报告干预使用情况。
  • 随访时805名参与者有治疗数据,613名有药物数据。

主要发现

  • 每周治疗总时间中位数为5.5小时(四分位距2.0-15.0)。
  • 仅33.4%的参与者报告接受行为治疗。
  • 16.3%的参与者使用至少一种精神药物。
  • 单变量分析和多元回归模型显示,入组前ASD诊断是治疗总时间的显著预测因素。
  • 单变量分析和多元逻辑模型显示,地点区域是精神药物使用的显著预测因素。

关键数值与推荐

  • 指南建议ASD幼儿接受强化非药物干预。
  • 相关症状可能使用精神药物治疗。

临床怎么用

  • 临床医生应关注ASD幼儿行为治疗的可及性和强度,并注意精神药物使用的地区差异。

局限性

  • 原文未报告研究局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: Guidelines suggest young children with autism spectrum disorder (ASD) receive intensive nonpharmacologic interventions. Additionally, associated symptoms may be treated with psychotropic medications. Actual intervention use by young children has not been well characterized. Our aim in this study was to describe interventions received by young children (3-6 years old) with ASD. The association with sociodemographic factors was also explored. METHODS: Data were analyzed from the Autism Speaks Autism Treatment Network (AS-ATN), a research registry of children with ASD from 17 sites in the United States and Canada. AS-ATN participants receive a diagnostic evaluation and treatment recommendations. Parents report intervention use at follow-up visits. At follow-up, 805 participants had data available about therapies received, and 613 had data available about medications received. RESULTS: The median total hours per week of therapy was 5.5 hours (interquartile range 2.0-15.0), and only 33.4% of participants were reported to be getting behaviorally based therapies. A univariate analysis and a multiple regression model predicting total therapy time showed that a diagnosis of ASD before enrollment in the AS-ATN was a significant predictor. Additionally, 16.3% of participants were on ≥1 psychotropic medication. A univariate analysis and a multiple logistic model predicting psychotropic medication use showed site region as a significant predictor. CONCLUSIONS: Relatively few young children with ASD are receiving behavioral therapies or total therapy hours at the recommended intensity. There is regional variability in psychotropic medication use. Further research is needed to improve access to evidence-based treatments for young children with ASD.

来源:Pediatrics,查看原文。版权归原作者所有。

引用

  1. Ziskind D, Bennett A, Jawad A, et al. Therapy and Psychotropic Medication Use in Young Children With Autism Spectrum Disorder. Pediatrics. 2020. PMID: 32238536. doi:10.1542/peds.2019-1895M

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。